Definition of Biologically Distinct Groups of Conjunctival Melanomas According to Etiological Factors and Implications for Precision Medicine.

BRAF CTNNB1 KIT NRAS conjunctival melanoma nevus primary acquired melanocytosis sun exposure

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
30 Jul 2021
Historique:
received: 06 07 2021
revised: 19 07 2021
accepted: 26 07 2021
entrez: 7 8 2021
pubmed: 8 8 2021
medline: 8 8 2021
Statut: epublish

Résumé

Conjunctival melanoma (ConjMel) is a potentially deadly ocular melanoma, originating from partially sunlight-exposed mucosa. We explored the mutational landscape of ConjMel and studied the correlation with etiological factors. We collected 47 primary ConjMel samples and performed next-generation sequencing of 400 genes. Hotspot mutations in

Identifiants

pubmed: 34359736
pii: cancers13153836
doi: 10.3390/cancers13153836
pmc: PMC8345091
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : European Commission
ID : 667787
Organisme : European Research Council
ID : ERC-ADG-2014 671262
Pays : International
Organisme : Cancer Research UK
ID : A27412 and A22902
Pays : United Kingdom
Organisme : Institut Curie
Organisme : Ligue Contre le Cancer
Organisme : Institut National de la Santé et de la Recherche Médicale

Références

Clin Cancer Res. 2008 Nov 1;14(21):6821-8
pubmed: 18980976
Blood. 2009 Jun 11;113(24):6182-92
pubmed: 19387008
Br J Cancer. 2018 May;118(9):1243-1247
pubmed: 29559732
J Hum Genet. 2016 Apr;61(4):361-2
pubmed: 26657935
Mol Genet Genomic Med. 2014 Jan;2(1):58-63
pubmed: 24498629
Ophthalmology. 2011 Feb;118(2):389-95.e1-2
pubmed: 20723990
J Oncol. 2012;2012:647684
pubmed: 22792102
Eur J Dermatol. 2017 Apr 1;27(2):160-165
pubmed: 28174141
Expert Rev Ophthalmol. 2014 Jun;9(3):185-204
pubmed: 25580155
Eye (Lond). 2013 Feb;27(2):142-52
pubmed: 23222568
Melanoma Res. 2020 Dec;30(6):533-542
pubmed: 33156594
Trans Am Ophthalmol Soc. 2007;105:61-71; discussion 71-2
pubmed: 18427595
Nat Rev Cancer. 2016 Jun;16(6):345-58
pubmed: 27125352
Arch Ophthalmol. 2004 Feb;122(2):167-75
pubmed: 14769591
Nucleic Acids Res. 2015 Jan;43(Database issue):D805-11
pubmed: 25355519
Nat Commun. 2020 Apr 20;11(1):1894
pubmed: 32313009
Mod Pathol. 2017 Feb;30(2):286-296
pubmed: 27739435
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
Nat Commun. 2019 Jul 18;10(1):3163
pubmed: 31320640
Arch Ophthalmol. 2001 May;119(5):670-6
pubmed: 11346394
Histopathology. 2006 Dec;49(6):612-21
pubmed: 17163846
JAMA Ophthalmol. 2015 Nov;133(11):1295-303
pubmed: 26425792
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):75-82
pubmed: 15623757
J Natl Compr Canc Netw. 2015 Sep;13(9):1066-70
pubmed: 26358791
Ann Oncol. 2017 Jun 1;28(6):1380-1387
pubmed: 28327988
Oncotarget. 2016 Jul 22;8(35):58021-58036
pubmed: 28938534
Int J Mol Sci. 2021 May 28;22(11):
pubmed: 34071371
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Clin Cancer Res. 2013 Jun 15;19(12):3143-52
pubmed: 23633454
J Clin Oncol. 2017 Jan 10;35(2):226-235
pubmed: 28056206
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Int J Clin Exp Pathol. 2014 Mar 15;7(4):1667-76
pubmed: 24817963
Cancer Res. 1999 Apr 15;59(8):1811-5
pubmed: 10213482
Br J Ophthalmol. 2009 Nov;93(11):1524-8
pubmed: 19628487
Ocul Oncol Pathol. 2020 Aug;6(4):293-296
pubmed: 33005620
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Ophthalmology. 2018 Jun;125(6):904-912
pubmed: 29371009
Oncol Rep. 2005 Feb;13(2):265-71
pubmed: 15643509
Acta Ophthalmol. 2013 Dec;91(8):e641-5
pubmed: 23742652
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
JAMA Ophthalmol. 2019 Dec 1;137(12):1444-1448
pubmed: 31647501
Clin Cancer Res. 2015 Jan 1;21(1):98-105
pubmed: 25370473
Br J Ophthalmol. 2020 Jul;104(7):1016-1021
pubmed: 31558492
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
BMC Cancer. 2017 Aug 10;17(1):536
pubmed: 28797232
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699
pubmed: 24030381
Genome Res. 1999 Aug;9(8):677-9
pubmed: 10447503
Melanoma Res. 2017 Jun;27(3):189-199
pubmed: 28296713
Acta Ophthalmol. 2016 Aug;94(5):463-70
pubmed: 27009410
Oncotarget. 2015 Feb 20;6(5):2604-14
pubmed: 25605252
Cancer Res. 2001 Sep 15;61(18):6656-9
pubmed: 11559529
Nature. 2017 May 11;545(7653):175-180
pubmed: 28467829
Nat Commun. 2021 Jan 11;12(1):259
pubmed: 33431815

Auteurs

Sophie Gardrat (S)

INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer and PSL Research University, Department of Biopathology, Institut Curie, PSL Research University, F-75005 Paris, France.

Alexandre Houy (A)

INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer, Department of Genetics, Institut Curie, PSL Research University, F-75005 Paris, France.

Kelly Brooks (K)

Molecular Oncology Group, CRUK Manchester Institute, The University of Manchester, Alderley Park, Manchester M13 9PL, UK.
QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.

Nathalie Cassoux (N)

Department of Ocular Oncology, Faculty of Medicine, Institut Curie, Université de Paris Descartes, F-75005 Paris, France.

Raymond Barnhill (R)

Department of Biopathology, Institut Curie, PSL Research University, F-75005 Paris, France.

Stéphane Dayot (S)

INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer, Department of Genetics, Institut Curie, PSL Research University, F-75005 Paris, France.

Ivan Bièche (I)

INSERM U1016, Institut Curie, Department of Genetics, Faculty of Pharmaceutical and Biological Sciences, Université de Paris, F-75005 Paris, France.

Virginie Raynal (V)

Institut Curie Genomics of Excellence (ICGex) Platform, Institut Curie, PSL Research University, F-75005 Paris, France.

Sylvain Baulande (S)

Institut Curie Genomics of Excellence (ICGex) Platform, Institut Curie, PSL Research University, F-75005 Paris, France.

Richard Marais (R)

Molecular Oncology Group, CRUK Manchester Institute, The University of Manchester, Alderley Park, Manchester M13 9PL, UK.

Sergio Roman-Roman (S)

Translational Research Department, Institut Curie, PSL Research University, F-75005 Paris, France.

Marc-Henri Stern (MH)

INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer, Department of Genetics, Institut Curie, PSL Research University, F-75005 Paris, France.

Manuel Rodrigues (M)

INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer, Department of Genetics, Institut Curie, PSL Research University, F-75005 Paris, France.
Department of Medical Oncology, Institut Curie, PSL Research University, F-75005, Paris, France.

Classifications MeSH